Former chair critiques USPSTF hiatus, restructuring

Clinical takeaway: Current USPSTF recommendations predate July 2025. A former chair's account explains the gap and what to watch as the reconstituted panel resumes work. 

Few panels carry more weight in primary care than the US Preventive Services Task Force (USPSTF). Its grades set what insurers must cover at no cost to patients, and its recommendations steer daily screening decisions. So, when eight new members joined earlier this month, a specialist-heavy slate that drew an AMA warning over thinned primary care representation. The question for clinicians wasn't only who now sits on the panel. It was what became of the work underway when its output went quiet. 

Michael Silverstein, MD, MPH, of Brown University's School of Public Health, chaired the panel in the year before the meeting cancellations began in July 2025, and the chair and vice chair who led the panel after him were removed this spring. Writing in Annals of Internal Medicine, he describes that stretch of time from the inside with the volunteer panel keeping to its weekly schedule even as its finished work stopped reaching clinicians. 

By his account, the pause was not for lack of finished work. The task force finalized a cervical cancer screening recommendation in fall 2025, built on new evidence for human papillomavirus self-testing and modeling of when screening should start, how often it should run, and when it should stop. The panel posted a draft for public comment, incorporated hundreds of responses into a final version, but the recommendation never published. A second topic, preventing cardiovascular disease through lifestyle interventions, was scheduled for votes in July and November 2025; both meetings were canceled before the panel could act. 

The blockages ran wider than those two topics, he writes. Reviews underway during the period covered cervical and prostate cancer screening, cognitive impairment, early introduction of allergenic foods to infants, and tobacco cessation in children and adolescents, and each was interrupted — some before a formal vote, others after votes had been taken but before public comment or release. The panel has published no recommendation since July 2025, which leaves the guidance in current use, and the coverage requirements tied to its top grades, running on evidence reviews that predate the pause. 

Eight new members joined eight continuing ones earlier this month, with Seth J. Corey, MD, MPH, a pediatric hematologist-oncologist at Cleveland Clinic, as chair. Five of the eight came from specialty practice, a first for a panel historically drawn from primary care and prevention, and the AMA's response centered on what thinner generalist representation could mean for recommendations built for primary care. The American College of Physicians followed with a call for the panel to conduct its work "free from political interference" and for member selection that is transparent and vetted for competency in evidence review. 

"Despite its efforts, the task force has been blocked from publishing even a single recommendation since July 2025," Silverstein writes. "This means that primary care providers across the country may be following cancer, heart disease, or other prevention guidelines that are based on outdated evidence, and Americans are possibly being denied insurance coverage for highly effective services." 

Source: Silverstein M. (2026 Sep 29) Ann Intern Med. Strong Science Needs Strong Defenders: What I Learned From My Colleagues on the U.S. Preventive Services Task Force